MEDA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MEDA, also known as 3-methoxy-4,5-ethylenedioxyamphetamine or as 5-methoxy-EDA, is a chemical compound of the phenethylamine, amphetamine, and EDxx families.[1][2] It is the EDxx analogue of the MDxx psychedelic and entactogen MMDA (5-methoxy-MDA).[1][2][3] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists MEDA's dose as greater than 200 mg orally and its duration as unknown.[1][2] MEDA produced few to no effects at tested doses.[1][2] The chemical synthesis of MEDA has been described.[1] MEDA was first described in the scientific literature by Shulgin in 1964.[3] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]
- None
| Clinical data | |
|---|---|
| Other names | 3-Methoxy-4,5-ethylenedioxyamphetamine; 5-Methoxy-3,4-ethylenedioxyamphetamine; 5-Methoxy-EDA; 5-MeO-EDA |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C12H17NO3 |
| Molar mass | 223.272 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
See also
- Substituted ethylenedioxyphenethylamine
- MTDA (5-methoxy-TDA)